1. Home
  2. STKS vs LUNG Comparison

STKS vs LUNG Comparison

Compare STKS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

N/A

Current Price

$1.80

Market Cap

74.3M

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.64

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
LUNG
Founded
2004
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
72.2M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
STKS
LUNG
Price
$1.80
$1.64
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
$4.50
$5.38
AVG Volume (30 Days)
27.0K
639.0K
Earning Date
06-15-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$673,344,000.00
$90,497,000.00
Revenue This Year
$23.94
$6.20
Revenue Next Year
$5.93
$21.61
P/E Ratio
N/A
N/A
Revenue Growth
102.35
8.01
52 Week Low
$1.70
$1.31
52 Week High
$5.19
$8.10

Technical Indicators

Market Signals
Indicator
STKS
LUNG
Relative Strength Index (RSI) 39.62 47.75
Support Level $1.70 $1.44
Resistance Level $2.08 $1.69
Average True Range (ATR) 0.14 0.17
MACD -0.02 0.01
Stochastic Oscillator 13.58 27.33

Price Performance

Historical Comparison
STKS
LUNG

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: